Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Application
Filed:
October 3, 2013
Publication date:
May 12, 2016
Applicant:
ROCHE GLYCART AG
Inventors:
Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo Umaña
Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
April 26, 2016
Assignee:
Roche Glycart AG
Inventors:
Pablo Umaña, Joël Jean-Mairet, James E. Bailey
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
Type:
Application
Filed:
December 11, 2015
Publication date:
March 31, 2016
Applicant:
Roche Glycart AG
Inventors:
Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
Abstract: The present invention relates to nucleic acids encoding anti-CD20 antigen binding molecules (ABMs). In particular embodiments, the present invention relates to nucleic acid encoding recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. In addition, the present invention relates to vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Type:
Grant
Filed:
November 5, 2004
Date of Patent:
March 29, 2016
Assignee:
Roche GlycArt AG
Inventors:
Pablo Umaña, Peter Brünker, Claudia Ferrara Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
Abstract: Herein is reported a multi-function protein, characterized in that it comprises exactly one antigen presenting domain, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a ?2-microglobulin, and (ii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a ?2-microglobulin, and (iii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen.
Type:
Application
Filed:
May 28, 2015
Publication date:
March 24, 2016
Applicant:
Roche Glycart AG
Inventors:
Christian Klein, Hendrik Knoetgen, Martina Schmittnaegel, Pablo Umana
Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
Type:
Application
Filed:
May 26, 2015
Publication date:
March 17, 2016
Applicant:
Roche GlycArt AG
Inventors:
Ekkehard MÖSSNER, Thomas U. Hofer, Ralf Jörg Hosse, Pablo Umana
Abstract: The present invention relates to a non-human animal comprising a humanized low affinity FcgR locus. Also provided herein is the use of said non-human animal for determining in vivo efficacy of antibodies, and methods for determining in vivo efficacy of antibodies.
Type:
Application
Filed:
October 29, 2012
Publication date:
March 3, 2016
Applicant:
Roche Glycart AG
Inventors:
Daniel Breustedt, Christian Gerdes, Antonio Iglesias, Pablo Umana
Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
Type:
Grant
Filed:
February 7, 2012
Date of Patent:
February 23, 2016
Assignee:
Roche Glycart AG
Inventors:
Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valerla G. Nicolini, Pablo Umana
Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody.
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.
Type:
Application
Filed:
June 16, 2014
Publication date:
January 7, 2016
Applicant:
ROCHE GLYCART AG
Inventors:
GEORG FERTIG, THOMAS FRIESS, CHRISTIAN KLEIN, PABLO UMANA
Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
Type:
Application
Filed:
June 5, 2014
Publication date:
January 7, 2016
Applicant:
ROCHE GLYCART AG
Inventors:
CHARLES DUMONTET, THOMAS FRIESS, FRANK HERTING, CHRISTIAN KLEIN, PABLO UMANA
Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
December 8, 2015
Assignee:
Roche Glycart AG
Inventors:
Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
Type:
Application
Filed:
August 6, 2013
Publication date:
October 22, 2015
Applicant:
ROCHE GLYCART AG
Inventors:
Thomas Hofer, Changhua Ji, Ekkehard Moessner, Pablo Umana
Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.
Type:
Application
Filed:
June 15, 2015
Publication date:
October 1, 2015
Applicant:
ROCHE GLYCART AG
Inventors:
Martin Dreyling, Daniel Alexander Heinrich, Frank Herting, Christian Klein
Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
Type:
Application
Filed:
March 23, 2015
Publication date:
October 1, 2015
Applicant:
Roche GlycArt AG
Inventors:
Pablo UMAÑA, Joël JEAN-MAIRET, James E. BAILEY